Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,806 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Type 1 Diabetes Mellitus Clear all

Conditions: Type 1 Diabetes
Interventions: Pramlintide acetate, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Type 1
Interventions: Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Hamilton, New Jersey • New Brunswick, New Jersey

Conditions: Diabetes Mellitus, Type 1
Interventions: Accu-Chek® CONNECT DMS, DMS; Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 7 Years to 18 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 10 more

Conditions: Diabetes Mellitus Type I
Interventions: Mental Health Symptoms, Self-efficacy regarding self-care and diabetes management, Parenting Styles; Behavioral
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 12 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Obesity, Overweight, Type 1 Diabetes Mellitus
Interventions: No intervention; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 7 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 1 Diabetes
Interventions: Predictive Low Glucose Management Feature in Insulin pump; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 14 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Escondido, California • Stanford, California • Walnut Creek, California + 5 more

Conditions: Diabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Immune System Diseases, Metabolic Diseases
Interventions: Glutamine vs. Placebo, Exercise; Drug · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Escondido, California • Lincoln, California • Walnut Creek, California + 19 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Regular Insulin, Humalog; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes
Interventions: TeenCope, Managing Diabetes; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Tucson, Arizona • New Haven, Connecticut • Miami, Florida + 1 more

Conditions: Type 1 Diabetes
Interventions: Predictive Low Glucose Minimizer; Device
Lead sponsor: Animas Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 17 Years
Enrollment: 46 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Tele-Monitor DM; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Antioxidant Cocktail, Resveratrol, Placebo; Dietary Supplement · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Augusta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-04603629, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more

Conditions: Diabetes Mellitus, Type II
Interventions: GOLO RELEASE; Dietary Supplement
Lead sponsor: Golo; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Valparaiso, Indiana

Conditions: Diabetes Mellitus, Type I
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 10 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 5
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 2 more

Conditions: Type 1 Diabetes
Interventions: Sugar Sleuth; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 25 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type I Diabetes
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 7 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
Interventions: R-5280, Placebo; Drug · Other
Lead sponsor: Rise Therapeutics LLC; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Plantation, Florida • Rochester, Minnesota • Dallas, Texas

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions: SB-509, Placebo; Biological · Other
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 19
States / cities: La Jolla, California • Lakewood, California • Lomita, California + 15 more

Conditions: Type 1 Diabetes Mellitus, Hypoglycemia
Interventions: EnMPC (Ensemble Model Predictive Control) AP Controller, rMPC (Naïve Model Predictive Control) AP Controller; Device
Lead sponsor: Marc Breton; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus
Interventions: Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

Accu-Chek® CONNECT at School (CATS) Pediatric Study

Mental Health Screenings in Adolescents With Type I Diabetes

Islet Transplantation for Type 1 Diabetes

The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children

In Clinic Evaluation of the PLGM Feature

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

Impact of Hybrid Closed-Loop Systems on Sleep and Psychosocial Outcomes in Youth With T1D and Their Parents

Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus

Estrogen and Diabetes

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

GOLO Open-Label Pilot 1

Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes

Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control

Management of Type 1 Diabetes Among Adolescents

R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery